Igniva

Igniva™ is Aganitha's integrated suite of reasoning-first AI agents purpose-built to accelerate therapeutic R&D in biopharma. By combining physics-informed biology and chemistry with multi-modal data integration, generative AI, and explainable AI, Igniva™ delivers interpretable, scalable, and regulatory-ready outputs that transform complex biomedical data into actionable discoveries. Its modular architecture supports human oversight at every stage, making it suitable for R&D teams across drug discovery and development.

Igniva™ serves as an end-to-end solution by integrating seamlessly with a family of specialized engines, each addressing a distinct challenge in the therapeutic discovery pipeline. Together, these components span target identification, protein engineering, antibody design, sequencing data management, and computational chemistry.

DBTIPS™ — Disease Biomarker and Target Insights Platform & Services

• Literature Insights: Automatically scans, summarizes, and highlights key research articles while tracking the timeline of scientific progress for each disease or target.
• Market Intelligence: Assesses competitive landscape, pipelines, and commercial potential to prioritize high-value opportunities.
• Multi-omics Integration: Combines signals from multi-omics data to uncover disease mechanisms and validate targets.
• Patient & Stakeholder Perspectives: Captures patient experiences with diseases and medications, along with insights from key opinion leaders and healthcare professionals, to align science with real-world unmet needs.
• Target Prioritization: Evaluates safety liabilities, tractability, and risk profiles to enable evidence-based target ranking and go/no-go decisions.
• Unifies data collation, biomarker and target assessment, and contextual patient insights into a single, evidence-rich workflow for systematic early discovery decision-making.

DISTILL™ — AI-Powered Single-Cell Omics Platform

• Designed to manage the complexity of single-cell RNA sequencing data for disease mechanism and biomarker identification, supporting the process from lab bench to clinical insights.
• Collaborative by design: Connects diverse professionals across teams.
• Iterative and exploratory: Allows analyses to be revisited and continuously refined.
• Meta-study ready: Enables cross-study comparisons for broader biological context.
• Next-generation LLM integrated: Supports plain-language biological queries for accessible data exploration.
• Integrated into agentic AI workflows: Prioritizes targets and validates mechanisms of action within broader discovery pipelines.

ACE™ — Enzyme Characterization and Optimization Platform

• A GenAI-powered platform for in silico enzyme characterization and optimization, accelerating design across therapeutic and biocatalysis domains.
• Combines ancestral sequence reconstruction, protein language models, and molecular dynamics with generative AI workflows.
• Predicts key properties including thermal stability, solubility, and enzymatic activity.
• Identifies evolutionarily favorable mutations and models three-dimensional protein structures.
• Integrates ML-directed evolution to streamline the discovery of high-performance enzyme variants.

NGS DataWorks™ — Next-Generation Sequencing Data Analysis

• An AI-powered, scientist-friendly platform for NGS data analysis designed to eliminate technical bottlenecks and accelerate discovery.
• Orchestrates custom NGS workflows spanning somatic mutation detection, tumor mutational burden profiling, rare disease applications, and functional genomics.
• Operates across private cloud or HPC environments for flexible and scalable analysis.
• Offers infrastructure-as-code deployment, automated quality control, and expert support.
• Transforms multi-omics sequencing data into efficient, customized insights without requiring deep bioinformatics expertise.

Igniva™ for Chemistry — Computational Chemistry Suite

• A modular AI-powered suite spanning the full spectrum of computational chemistry, from structural biology to molecule and material discovery to chemistry, manufacturing, and controls (CMC).
• Structural Biology: Modeling novel protein targets, antibody stability, AAV design, and related applications.
• Molecule & Material Discovery: Covers small molecules, covalent binders, PROTACs, antibodies, surfactants, biopolymers, fragrance molecules, and more.
• CMC: Includes reaction modeling, formulation design, crystal structure prediction, and digital twins of bioprocesses.
• Fuses generative AI and large language models with physics-first methods such as quantum mechanics (QM) and molecular dynamics (MD) to explore new chemical spaces and accelerate process development.

Solution Coverage Across the Drug Discovery Value Chain

• Target and biomarker research spanning genomics, transcriptomics, proteomics, and organoid research.
• Small molecule engineering including virtual screening, covalent binders, and PROTACs.
• Antibody engineering covering characterization, de novo generation, optimization, virtual screening, and antibody-drug conjugates (ADCs).
• RNA therapies including ASO therapies, mRNA platforms, and lipid nanoparticle (LNP) engineering.
• Gene therapies, peptide modeling, and enzyme engineering.
• CMC capabilities including stability analysis, reaction modeling, catalysis modeling, and solid form de-risking.

Igniva™ is developed and maintained by multidisciplinary teams at Aganitha with strong academic credentials and blended expertise in biological and chemical sciences, data science, and enterprise-grade technology. The platform is designed for deployment across private cloud and HPC environments, with continuous investment in training, research, and infrastructure to support biopharma R&D clients across immunology, rare diseases, oncology, and CNS disorders.